KC
NVNO

Kepos Capital’s enVVeno Medical NVNO Stock Holding History

Kepos Capital’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,429
Closed -$319K – 549
2022
Q1 		$319K Hold
1,429
– – 0.02% 262
2021
Q4 		$330K Buy
+1,429
New +$402K 0.03% 328
2021
Q3 		– Sell
-2,041
Closed -$491K – 577
2021
Q2 		$491K Hold
2,041
– – 0.04% 311
2021
Q1 		$476K Buy
+2,041
New +$568K 0.03% 310

Other funds holding NVNO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $563M AUM 20.97% 1-Year Est. Return

Kepos Capital's NVNO Position: Q2 2022 in Review

Kepos Capital sold out of enVVeno Medical (NVNO) in Q2 2022, closing a stake of 1,429 shares — an estimated $319K sold.

Kepos Capital first reported a position in NVNO in Q1 2021 and held it in 4 quarters. The position peaked at $491K in Q2 2021. 21 funds tracked by Wall St. Rank hold NVNO as of Q2 2022.

  • Kepos Capital reported no remaining enVVeno Medical position as of Q2 2022 after selling out during the quarter.
  • Kepos Capital sold 1,429 enVVeno Medical shares in Q2 2022, an estimated $319K.
  • Kepos Capital first reported a position in enVVeno Medical in Q1 2021 and held it in 4 quarters.
  • Kepos Capital's enVVeno Medical position peaked at $491K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held enVVeno Medical as of Q2 2022.

Based on Kepos Capital's 13F filing for Q2 2022, filed 12 Aug 2022.